Charles A Scanga Selected Research

Tuberculosis (Tuberculoses)

11/2023	Intravenous Bacille Calmette-Guérin vaccination protects simian immunodeficiency virus-infected macaques from tuberculosis.
1/2023	The Endogenous Retinoic Acid Receptor Pathway Is Exploited by Mycobacterium tuberculosis during Infection, Both In Vitro and In Vivo.
1/2023	Mycobacterium tuberculosis-Specific CD4 T Cells Expressing Transcription Factors T-Bet or RORγT Associate with Bacterial Control in Granulomas.
1/2023	Host Immunity to Mycobacterium tuberculosis Infection Is Similar in Simian Immunodeficiency Virus (SIV)-Infected, Antiretroviral Therapy-Treated and SIV-Naïve Juvenile Macaques.
1/2023	Optimizing tuberculosis treatment efficacy: Comparing the standard regimen with Moxifloxacin-containing regimens.
2/2022	Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid.
1/2020	Prevention of tuberculosis in macaques after intravenous BCG immunization.
1/2019	Boosting BCG with proteins or rAd5 does not enhance protection against tuberculosis in rhesus macaques.
10/2018	Identification of Mycobacterium tuberculosis using volatile biomarkers in culture and exhaled breath.
1/2017	Positron Emission Tomography Imaging of Macaques with Tuberculosis Identifies Temporal Changes in Granuloma Glucose Metabolism and Integrin α4β1-Expressing Immune Cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Charles A Scanga Research Topics

Disease

21	Tuberculosis (Tuberculoses) 11/2023 - 12/2003
20	Infections 04/2024 - 08/2003
7	Granuloma 12/2023 - 01/2017
3	Pulmonary Tuberculosis 11/2023 - 08/2014
2	COVID-19 04/2024 - 01/2020
2	Inflammation (Inflammations) 01/2017 - 01/2007
2	Pneumonia (Pneumonitis) 01/2017 - 01/2017
1	Breakthrough Infections 04/2024
1	Measles 04/2024
1	Reinfection 12/2023
1	Disease Progression 01/2023
1	Lung Diseases (Lung Disease) 01/2022
1	Influenza in Birds (Avian Flu) 01/2017
1	Coinfection 01/2017
1	Cytokine Release Syndrome 01/2017
1	Toxoplasmosis 06/2002

Drug/Important Bio-Agent (IBA)

10	VaccinesIBA 04/2024 - 05/2012
5	CytokinesIBA 01/2017 - 04/2005
5	Interleukin-12 (IL 12)IBA 12/2005 - 06/2002
4	LigandsIBA 12/2023 - 12/2003
4	Proteins (Proteins, Gene)FDA Link 01/2023 - 08/2003
4	AerosolsIBA 01/2020 - 12/2003
3	RNA (Ribonucleic Acid)IBA 12/2023 - 10/2022
3	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2017
3	AntigensIBA 01/2019 - 01/2007
3	Messenger RNA (mRNA)IBA 01/2007 - 08/2003
3	Toll-Like Receptors (Toll-Like Receptor)IBA 12/2005 - 11/2003
2	Immunoglobulin G (IgG)IBA 01/2023 - 01/2020
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2023 - 01/2017
2	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2017
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2021 - 01/2017
2	EnzymesIBA 01/2017 - 03/2010
1	SARS-CoV-2 spike proteinIBA 04/2024
1	Interleukin-15 (Interleukin 15)IBA 12/2023
1	Sialic Acid Binding Immunoglobulin-like LectinsIBA 01/2023
1	Moxifloxacin (Avelox)FDA Link 01/2023
1	Transcription Factors (Transcription Factor)IBA 01/2023
1	Immunodominant EpitopesIBA 01/2023
1	Conditioned Culture MediaIBA 01/2023
1	Retinoic Acid Receptors (Retinoic Acid Receptor)IBA 01/2023
1	Benzoic Acid (Potassium Benzoate)FDA Link 01/2023
1	Clofazimine (Lamprene)FDA Link 02/2022
1	Complement System Proteins (Complement)IBA 01/2022
1	Formyl Peptide Receptors (Formyl Peptide Receptor)IBA 01/2021
1	Immunoglobulin M (IgM)IBA 01/2020
1	BCG Vaccine FDA Link 01/2020
1	IntegrinsIBA 01/2017
1	PeptidomimeticsIBA 01/2017
1	AntioxidantsIBA 01/2017
1	AlbuminsIBA 01/2017
1	Tuberculosis VaccinesIBA 01/2017
1	Integrin alpha4beta1 (VLA-4)IBA 01/2017
1	Heme Oxygenase-1IBA 01/2017
1	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 01/2016
1	Histocompatibility Antigens Class IIBA 05/2012
1	Leukotriene A4IBA 03/2010
1	EicosanoidsIBA 03/2010
1	HydrolasesIBA 03/2010
1	AcidsIBA 01/2007
1	lipoxin A4IBA 06/2005
1	LipoxinsIBA 06/2005
1	Nitric Oxide Synthase (NO Synthase)IBA 06/2005
1	Myeloid Differentiation Factor 88IBA 11/2003
1	Toll-Like Receptor 2IBA 11/2003

Therapy/Procedure

3	Therapeutics 01/2023 - 01/2017
1	Intravenous Administration 01/2020